Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.86
  • Today's Change-1.66 / -3.42%
  • Shares traded13.72m
  • 1 Year change+14.99%
  • Beta0.3766
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.

  • Revenue in USD (TTM)47.64bn
  • Net income in USD5.42bn
  • Incorporated1933
  • Employees34.10k
  • Location
    Bristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
  • Phone+1 (609) 252-4621
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BMY:NYQ since
announced
Transaction
value
2Seventy Bio IncDeal completed10 Mar 202510 Mar 2025Deal completed-23.29%238.66m
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regeneron Pharmaceuticals Inc14.09bn4.50bn60.43bn15.11k14.242.0612.104.2939.3039.30123.45271.600.39170.63472.61932,457.3012.5118.5213.8921.1386.6987.2231.9437.924.03--0.0843--8.2712.5511.6115.8415.46--
Zoetis Inc9.29bn2.52bn70.70bn13.80k28.5215.2223.437.615.575.5720.5410.440.65291.077.00672,898.6017.7715.2521.8318.3170.9870.1827.2226.321.0421.140.585628.938.338.146.0610.637.3221.37
Bristol-Myers Squibb Co47.64bn5.42bn98.74bn34.10k18.225.687.312.072.662.6623.448.540.49764.275.121,396,950.005.680.65367.690.817574.6976.6311.411.521.177.390.7402678.247.3213.06-211.50--8.347.91
Vertex Pharmaceuticals Inc11.10bn-988.90m123.14bn6.10k--7.47--11.09-3.88-3.8842.8664.200.47441.436.171,819,623.00-4.2314.06-5.0416.6786.0387.35-8.9126.282.29--0.00670.0011.6621.50-114.80--45.11--
Gilead Sciences Inc28.74bn5.97bn142.48bn17.60k24.237.4416.314.964.734.7322.7915.390.50983.456.351,632,671.0010.585.2613.636.3878.2978.4720.7612.541.237.800.5667108.476.045.08-91.53-38.34-8.714.10
Pfizer Inc62.46bn7.87bn146.57bn81.00k18.701.629.912.351.381.3810.9515.890.29111.465.47771,148.103.687.454.499.4374.5769.1012.6420.370.960412.260.406664.226.849.10275.82-5.272.323.13
Data as of Jul 11 2025. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD

Institutional shareholders

34.62%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2025181.48m8.94%
BlackRock Fund Advisorsas of 31 Mar 202597.77m4.82%
SSgA Funds Management, Inc.as of 31 Mar 202594.83m4.67%
JPMorgan Investment Management, Inc.as of 31 Mar 202568.85m3.39%
Capital Research & Management Co. (International Investors)as of 31 Mar 202566.47m3.28%
Charles Schwab Investment Management, Inc.as of 31 Mar 202560.61m2.99%
Geode Capital Management LLCas of 31 Mar 202545.45m2.24%
Norges Bank Investment Managementas of 31 Dec 202435.18m1.73%
Columbia Management Investment Advisers LLCas of 31 Mar 202529.02m1.43%
PRIMECAP Management Co.as of 31 Mar 202522.97m1.13%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.